Αποτελέσματα Αναζήτησης
14 Ιουλ 2020 · With the goal of developing a new class of anticoagulants associated with a lower risk of bleeding than currently available agents, dozens of drugs targeting the contact system are now in development.
12 Οκτ 2020 · Clinical evaluation of new anticoagulants often starts in patients undergoing joint replacement surgery because such patients are at high risk of postoperative venous thromboembolism, particularly asymptomatic deep vein thrombosis (DVT), which can be detected on routine venography.
19 Μαρ 2015 · Oral anticoagulants are widely used for long-term prevention and treatment of venous and arterial thromboembolism. Until recently, vitamin K antagonists, such as warfarin, were the only available oral anticoagulants.
Abstract. Summary. The limitations of heparin and warfarin have prompted the development of new anticoagulant drugs for prevention and treatment of venous and arterial thromboembolism. Novel parenteral agents include synthetic analogs of the pentasaccharide sequence of heparin that mediates its interaction with antithrombin.
By pooling data across indications for anticoagulation and including additional data from other phase 3 randomized clinical trials, our analysis demonstrates that novel oral anticoagulants reduce the risk of intraocular bleeding by approximately one-fifth compared with warfarin.
This article focuses on the rationale, development, and testing of these new agents with a concentration on those that have reached or completed phase 2 evaluation for at least one indication. Keywords: anticoagulant; coagulation; factor XI; factor XII; thrombosis.
18 Οκτ 2024 · Over the last decade, the advent of direct oral anticoagulants (DOACs) has rapidly changed the landscape of anticoagulation. In the early 2010s, DOACs became widely available for stroke prevention in atrial fibrillation and the treatment of venous thromboembolism.
